Appearance
The Brief
For: J&J Electrophysiology Leadership | Updated: February 2026
J&J has the only complete EP lab — PFA, RF, and mapping. VARIPULSE has cleared 40,000 procedures globally, the post-correction stroke rate is 0.22%, and per-procedure safety rates now favor VARIPULSE over every competitor. Two patient deaths (three MAUDE records) appeared in Nov-Dec 2025, but the rate-based story is stronger than the cohort-specific "no deaths" data J&J has cited to date.
The market: ~250,000 US AF ablations annually (CMS Medicare data x all-payer multiplier), growing ~12% YoY. CMS added cardiac ablation to ASCs effective January 1, 2026 — the biggest structural shift in EP access in two decades. J&J's PFA share: 10-20% and growing.
The PFA Scoreboard
| FARAPULSE | PulseSelect | Affera | VARIPULSE | |
|---|---|---|---|---|
| Est. procedures | 500,000+ | ~30,000 est | Not disclosed | ~40,000 |
| FDA adverse events | 2,409 | 1,041 | 401 | 260 |
| Deaths | 91 | 11 | 5 | 3 |
| Deaths per 10K procedures | 1.8 | 3.7 | — | 0.75 |
| Mfg defects per 10K | 5.7 | 44.3 | — | 3.0 |
| MAUDE reports per 1K procs | 4.8 | 34.7 | — | 6.5 |
FDA adverse event data, Jan 2024-Jan 2026. Procedures: BSC earnings (500K cumulative), MDT PR (~30K est), J&J Q4 2025 earnings (~40K). All global.
How to read this:
- VARIPULSE now has the lowest death rate per 10K (0.75) and lowest mfg defect rate (3.0) of any PFA platform with disclosed volumes.
- FARAPULSE still has the most procedures — but its per-procedure advantage is gone. At 500K procedures, FARAPULSE's death rate (1.8 per 10K) is 2.4x worse than VARIPULSE's.
- The reporting gap has narrowed. VARIPULSE's MAUDE reporting rate dropped from 87 to 6.5 per 1K procedures as volume grew. It's now comparable to FARAPULSE's 4.8 — within normal manufacturer variation, not a 7x inflation artifact.
- PulseSelect has the worst safety profile across every metric. Manufacturing defect rate (44.3 per 10K) is 8x FARAPULSE and 15x VARIPULSE.
Three Things That Matter
1. VARIPULSE Per-Procedure Rates Now Lead the Category
At ~40,000 procedures, VARIPULSE's per-procedure rates are no longer "unreliable small samples." They're the best in PFA: 0.75 deaths per 10K (vs 1.8 FARAPULSE), 3.0 mfg defects per 10K (vs 5.7 FARAPULSE), and a post-correction neurovascular event rate of 0.22% in 6,811 patients.
The comparison that now works: "Our death rate is half theirs. Our mfg defect rate is half theirs. And every one of our deaths has a full investigation."
2. FARAPULSE: 91 Deaths, Slowing Growth
91 deaths across 500,000+ procedures is ~0.02%. But 51 have "unknown" root cause per LLM extraction, and 4 were caused by a software bug (80% fatality from a product defect). BSC missed Q4 EP consensus by $33M — stock dropped 18% on Feb 4. Market share erosion has begun.
3. CMS Opened ASCs to Cardiac Ablation
Effective January 1, 2026, CMS added cardiac catheter ablation to ASC-covered procedures at $20,512 per PVI. This is the biggest site-of-service shift in EP in 20+ years. VARIPULSE's 87.9% same-day discharge rate (VARISURE data, 850 procedures) is an ASC-ready metric. But VARIPULSE requires CARTO ($500K). The ASC strategy decision is now urgent.
What To Do
This week:
- Update all field messaging with new per-procedure data. VARIPULSE now leads on death rate and mfg defect rate. This is the first time rate-based claims are defensible.
- Brief the field on BSC's Q4 miss. FARAPULSE growth is stalling. Accounts evaluating PFA platforms should know the market is shifting.
This quarter: 3. Build on the VARISURE and post-IFU data. 0.22% neurovascular rate in 6,811 patients and 87.9% same-day discharge are publishable, referenceable metrics. Get them into a peer-reviewed journal. 4. Launch an outcomes registry. BSC has MANIFEST-US (41,968 patients). J&J still has nothing comparable. The ~40,000 procedure milestone means you have the patient volume — you need the infrastructure to capture it. 5. Decide on ASCs. CMS opened the door January 1. Abbott Volt has a conscious sedation advantage. Affera has no capital cost. Every quarter without an ASC strategy is a quarter competitors build installed base. 6. Accelerate Omnypulse enrollment. The pilot (30 patients, 90% 12-month effectiveness, zero MRI-detected cerebral lesions) is the single best counter-narrative to the Varipulse stroke history. Fast-track the 440-patient IDE. 7. Monitor Abbott Volt. VOLT-AF IDE: 84.2% PAF effectiveness, zero hemolysis. Small sample but strong early signal. First MAUDE data expected Q1-Q2 2026.
The Mapping Snapshot
| System | Parent | FDA Events | Deaths | Design Flaws | Share |
|---|---|---|---|---|---|
| CARTO 3 | J&J | 87 | 2 | 4 | ~50%+ |
| Opal/RHYTHMIA | BSX | 650 | 0 | 5 | Growing |
| EnSite X | Abbott | 110 | 0 | 2 | Low |
| Affera Map | Medtronic | 1 | 0 | 0 | Growing fast |
CARTO: 20 years of evidence, 2 deaths (lowest in category), largest installed base. Opal/RHYTHMIA has more events (650) but zero deaths — mostly usability reports as BSC scales the platform. Affera's mapping function is built into the ablation catheter, so mapping-specific events appear under the Sphere-9 device (401 events, 5 deaths, 32 design flaws).
BSX is building toward integrated PFA + mapping: Opal HDx + FARAWAVE NAV, with Faraflex (single map+ablate catheter) completing first cases Feb 2025 and Farapoint (focal PFA) FDA-approved Jan 2026.
| Section | What It Covers |
|---|---|
| The PFA Race | Per-procedure rates, MANIFEST-US data, ADVENT 4-year, adoption trends |
| The Mapping War | CARTO vs Affera, CMS ASC rule, PFA class-wide risks |
| Your Playbook | Portfolio assessment, Omnypulse pilot, what to defend |
| Battle Cards | What to say and what not to say, by competitor |
| Method | Data sources, procedure volume estimates, limitations |
PFA market share (analyst surveys):
| Survey | BSC | Medtronic | J&J | Abbott |
|---|---|---|---|---|
| BTIG (Jan 2025) | 58% | 28% | 11% | 3% |
| Citi (Dec 2024) | 33% | 56% | 10% | — |
| BTIG projected 2026 | 48% | 29% | 20% | 3% |
Surveys disagree on BSC vs Medtronic. Agree on J&J: 10-20%, growing. BSC's Q4 miss and 18% stock decline suggest the BTIG 2026 projection (BSC declining to 48%) may be conservative.
FDA adverse event database (2.99M events), CMS Medicare procedure data (2021-2023), MANIFEST-US registry (41,968 patients), VARISURE Safety Survey (850 procedures), company earnings, analyst surveys. Through January 2026.